For example, patients who achieve an MRD-negative CR after less intensive therapy might have longer remissions than similar patients given more intensive therapy because the former have inherently more chemo-sensitive disease. The presence of "measurable residual disease" (MRD) is highly associated with relapse in patients achieving complete remission (CR) regardless of whether post-remission therapy includes allogeneic hematopoietic cell transplantation (HCT) [[1]]. On the other hand, patients who receive more intensive treatment might have longer remissions because such therapy produces "deeper" MRD-negative CRs, with depth difficult to evaluate with current methodology. [Extracted from the article]